Contrasting Innovative Eyewear (NASDAQ:LUCY) and Sanara MedTech (NASDAQ:SMTI)

Innovative Eyewear (NASDAQ:LUCY) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Volatility and Risk

Innovative Eyewear has a beta of 2.66, suggesting that its stock price is 166% more volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.

Insider & Institutional Ownership

1.0% of Innovative Eyewear shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 1.7% of Innovative Eyewear shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Innovative Eyewear and Sanara MedTech”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innovative Eyewear	$2.66 million	2.12	-$7.59 million	($1.69)	-0.52
Sanara MedTech	$107.48 million	1.96	-$37.56 million	($3.77)	-6.10

Innovative Eyewear has higher earnings, but lower revenue than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Innovative Eyewear, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Innovative Eyewear and Sanara MedTech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innovative Eyewear	1	1	0	0	1.50
Sanara MedTech	2	0	2	0	2.00

Sanara MedTech has a consensus target price of $34.00, suggesting a potential upside of 47.89%. Given Sanara MedTech’s stronger consensus rating and higher probable upside, analysts plainly believe Sanara MedTech is more favorable than Innovative Eyewear.

Profitability

This table compares Innovative Eyewear and Sanara MedTech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Innovative Eyewear	-272.42%	-83.37%	-76.02%
Sanara MedTech	-31.23%	-3.19%	-0.56%

Summary

Sanara MedTech beats Innovative Eyewear on 9 of the 14 factors compared between the two stocks.

About Innovative Eyewear

Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.

About Sanara MedTech

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.